Logo Logo
Switch Language to German

Schemionek, Mirle; Masouleh, Behzad Kharabi; Klaile, Yvonne; Krug, Utz; Hebestreit, Katja; Schubert, Claudia; Dugas, Martin; Büchner, Thomas; Wörmann, Bernhard; Hiddemann, Wolfgang; Berdel, Wolfgang E.; Brümmendorf, Tim H.; Mueller-Tidow, Carsten and Koschmieder, Steffen (2015): Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia.
In: PLOS ONE 10(5), e0125783 [PDF, 1MB]

[thumbnail of 10.1371_journal.pone.0125783.pdf]
Download (1MB)


The adapter protein metastasis suppressor 1 (MTSS1) is implicated as a tumor suppressor or tumor promoter, depending on the type of solid cancer. Here, we identified Mtss1 expression to be increased in AML subsets with favorable outcome, while suppressed in high risk AML patients. High expression of MTSS1 predicted better clinical outcome of patients with normal-karyotype AML. Mechanistically, MTSS1 expression was negatively regulated by FLT3-ITD signaling but enhanced by the AML1-ETO fusion protein. DNMT3B, a negative regulator of MTSS1, showed strong binding to the MTSS1 promoter in PML-RARA positive but not AML1-ETO positive cells, suggesting that AML1-ETO leads to derepression of MTSS1. Pharmacological treatment of AML cell lines carrying the FLT3-ITD mutation with the specific FLT3 inhibitor PKC-412 caused upregulation of MTSS1. Moreover, treatment of acute promyelocytic cells (APL) with all-trans retinoic acid (ATRA) increased MTSS1 mRNA levels. Taken together, our findings suggest that MTSS1 might have a context-dependent function and could act as a tumor suppressor, which is pharmacologically targetable in AML patients.

Actions (login required)

View Item View Item